Drugs / MRTX0902
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05578092 | Dec 2022 → Feb 2026 | colorectal cancer, non-small cell lung carcinoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-05 | Verastem, Inc. | Results Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 verastem.com ↗
The SOS1 Inhibitor MRTX0902 Demonstrates Activity Across Cancer Models with Mutations in Proximal Components of the RAS-MAPK pathway |
All press releases naming this drug 1 release
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRTX0902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05578092 ↗ |
| Known as | UNII-CRG69FR93G | ChEMBL registry synonym — accepted as the source's own label CHEMBL5192659 ↗ |
| Action | Inhibit | “SOS1 inhibitor” NCT05578092 ↗ |
| Modality | Small molecule | — CHEMBL5192659 ↗ |
| Target | SOS1 | “SOS1 inhibitor” NCT05578092 ↗ |